期刊文献+

厄他培南治疗老年人社区获得性肺炎 被引量:3

原文传递
导出
摘要 由于年龄和基础疾病的原因,老年人肺炎的临床表现常不典型,多数起病隐匿常缺乏咳嗽、咳痰、发热、胸痛及肺部湿啰音等肺炎的特征性表现。厄他培南是种新型1β-甲基碳青酶烯类抗生素,具有抗菌谱广、药物代谢动力学参数优良、不良反应少等特点,
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2009年第10期845-846,共2页 Chinese Journal of Geriatrics
  • 相关文献

参考文献3

二级参考文献35

  • 1孙铁英,刘兵,扬敏.社区获得性肺炎老年住院患者的临床分析[J].中华老年医学杂志,2005,24(2):100-102. 被引量:111
  • 2[1]Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolate[J]. Antimicrob Agents Chemother, 1999,43:1170-1176
  • 3[2]Friedland IR, Isaacs R, Mixson LA, et al. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem[J]. Diagn Microbiol Infect Dis, 2002,43:61-64
  • 4[3]Vetter N, Cambronero-Hernandez E, Rohlf J, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia[J]. Clin Ther,2002,24:1770-1785
  • 5[4]Aldridge KE. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes[J]. Diagn Microbiol Infect Dis, 2002,44:181-186
  • 6[5]Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers[J]. Antimicrob Agents Chemother,2001,45 : 1915-1918
  • 7[6]Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia[J]. Antimicrob Agents Chemother,2001,45:1860-1867
  • 8[7]Goldstein EJ, Citron DM, Vreni Merriam C, et al. Comparative In vitro activities of ertapenem (MK-0826) against 1,001anaerobes isolated from human intra-abdominal infections[J].Antimicrob Agents Chemother, 2000,44: 2389-2394
  • 9[8]Betriu C, Sanchez A, Palau ML, et al. In vitro activities of MK-0826 and 16 other antimicrobials against bacteroides fragilis group strains [J]. Antimicrob Agents Chemother, 2001,45;2372-2374
  • 10[9]Cottagnoud P, Pfister M, Cottagnoud M, et al. Activities of ertapenem, a new long-acting carbapenem, against penicillinsensitive or -resistant pneumococci in experimental meningitis [J]. Antimicrob Agents Chemother, 2003,47 : 1943-1947

共引文献26

同被引文献22

  • 1陆再英,钟南山.内科学[M].北京:人民卫生出版社,2008:121.
  • 2Marik PE.Aspiration pneumonitis and aspiratio pneumonia[J].N Engl J reed,2001,34(4):665.
  • 3Pikus L,Levine MS,Yang YX,et al .Videofluoroseopic studies of swallowing dysfunction and the relative risk of pneumonia[J].AJR Am J Roentgenol,2003,18(10): 1613.
  • 4Kattan JN,Villegas MV,Quinn JP.New developments car-bapenems[J].Clin Microbiol Infect,2008,14(12):1102-1111.
  • 5Fong JJ,Rose L,Radigan EA.Clinical outcomes with ertap-enem as a first-line treatment option of lnfections caused byextended-spectrumβ-lactamase-producing gram-negative bac-teria[J].Ann Pharmacother,2012,46(3):347-352.
  • 6Park YS,Adams-Haduch JM,Shutt KA.Clinical and micro-biologic characteristics of cephalosporin-resistant Escherichiacoli at three centers in the United States[J].Antimicrob A-gents Chemother,2012,56(4):1870-1876.
  • 7Denis Frasca,Sandrine Marchand,Franck Petitpas,Pharma-cokinetics of ertapenem following lntravenous and subcutane-ous Infusions in patients[J].Antimicrob Agents Chemother,2010,54(2):924-926.
  • 8TEPPLER H, GESSER RM, FRIEDLAND IR. Safety and tolerability of ertapenem [J]. Antimicrob Chemother, 2004, 53 (2) : 75-81.
  • 9KOPPEL BS, HAUSER WA, POLITIS C, et al. Seizures in the critically ill: the role of imipenem[J]. Epilepsia 2001, 42 (12): 1590-1593.
  • 10LIVERMORE DM, SEFTON AM, SCOTT GM. Properties and potential of ertapenem[J]. J Antimierob Chemother, 2003, 52(3 ) : 331-344.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部